Effect of baseline levels on response of high-density lipoprotein cholesterol to hypolipidemic treatment

American Journal of Cardiology

Volumn 92, Issue 11, 2003, Pages 1339-1342

  Kolovou, Genovefa D ^a   Daskalova, Deliana C ^b   Petropoulos, Ilias I ^b   Anagnostopoulou, Katherine K ^b   Bilianou, Helen I ^b   Pilatis, Nektarios D ^b   Pavlidis, Antonis N ^b   Cokkinos, Dennis V ^b  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; CREATININE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EXAMINATION; CLINICAL PROTOCOL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET; DYSLIPIDEMIA; FEMALE; HUMAN; HYPOLIPEMIA; HYPOTHESIS; INFORMED CONSENT; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 0242487830     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.08.022     Document Type: Article

References (20)

1. Gordon D.J., Rifkind B.M. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med. 321:1989;1311-1316.
2. Ronnemaa T., Laakso M., Kallio V., Pyorala K., Marniemi J., Puukka P. Serum lipids, lipoproteins, and apolipoproteins and the excessive occurrence of coronary heart disease in non-insulin-dependent diabetic patients. Am J Epidemiol. 130:1989;632-645.
3. Badimon J.J., Badimon L., Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 85:1990;1234-1241.
4. Pedersen T.R., Olsson A.G., Faergeman O., Kjekshus J., Wedel H., Berg K., Wilhelmsen L., Haghfelt T., Thorgeirsson G., Pyorala K., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 97:1998;1453-1460.
5. Gotto A.M. Jr, Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., Jou J.Y., Langendorfer A., Beere P.A., Watson D.J., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 101:2000;477-484.
6. Boden W.E. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial . Am J Cardiol. 86:(suppl):2000;19L-22L.
7. Gotto A.M. Jr. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease a working group report . Circulation. 103:2001;2213-2218.
8. Robins S.J., Collins D., Wittes J.T., Papademetriou V., Deedwania P.C., Schaefer E.J., McNamara J.R., Kashyap M.L., Hershman J.M., Wexler L.F., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events VA-HIT: a randomized controlled trial . JAMA. 285:2001;1585-1591.
9. Ballantyne C.M., Herd J.A., Ferlic L.L., Dunn J.K., Farmer J.A., Jones P.H., Schein J.R., Gotto A.M. Jr. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation. 99:1999;736-743.
10. Boden W.E., Pearson T.A. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. Am J Cardiol. 85:2000;645-650.
11. Mikhailidis D.P., Wierzbicki A.S. HDL-cholesterol and the treatment of coronary heart disease contrasting effects of atorvastatin and simvastatin . Curr Med Res Opin. 16:2000;139-146.
12. Assmann G. Pro and con high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management . Am J Cardiol. 87:(suppl):2001;2B-7B.
13. Gotto A.M. Jr. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J. 144:2002;S33-S42.
14. Kolovou G., Cokkinos D.V. Low serum levels of high-density lipoprotein cholesterol and hypolipidaemic treatment. Curr Med Res Opin. 18:2002;265-268.
15. Sacks F.M. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease expert group recommendations . Am J Cardiol. 90:2002;139-143.
16. Crouse J.R. III, Frohlich J., Ose L., Mercuri M., Tobert J.A. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol. 83:1999;1476-1477.
17. Kolovou G.D., Fostinis Y.P., Athanassopoulos G., Manolis A.J., Cokkinos D.V. Differential response of high-density lipoproteins to first-step lipid-lowering diet according to their initial level. Coron Artery Dis. 5:1994;359-364.
18. Kolovou G.D., Fostinis Y.P., Bilianou H.J., Cokkinos D.V. Response of high-density lipoproteins to hypolipidemic drugs according to their initial level. Am J Cardiol. 75:1995;293-295.
19. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
20. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.